Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Celgene
Pharma
BMS skates again on $6.4B Celgene shareholder lawsuit
A U.S. judge has dismissed a lawsuit claiming that BMS slow-walked its FDA approval of Breyanzi to avoid paying $6.4B to Celgene shareholders.
Kevin Dunleavy
Oct 1, 2024 10:45am
BMS accused of anticompetitive tactics to keep Pomalyst chugging
Sep 7, 2023 11:31am
BMS does away with the 'old me' in latest Zeposia DTC campaign
Jul 13, 2023 9:25am
Bristol Myers dodges one Celgene CVR suit, but more to come
Mar 2, 2023 10:40am
BMS debuts spot for Sotyktu during the Grammys
Feb 8, 2023 7:25am
BMS, generics companies face new suit over Revlimid 'monopoly'
Nov 22, 2022 11:38am
